Prevention of acquired transient defect in platelet plug formation by infused prostacyclin.

Cardiopulmonary bypass in baboons produced transient severe platelet dysfunction (bleeding times prolonged to 27.8 +/- 1.4 min compared with 3.9 +/- 0.7 baseline) that was associated with a parallel release of platelet alpha-granule proteins into plasma (platelet factor 4 and beta-thromboglobulin levels of 28.8 +/- 9.3 and 20.0 +/- 1.8 ng/ml, respectively) and their clearance into urine with a reciprocal depletion from circulating platelets. In contrast, platelet-dense granules did not undergo significant release. The bleeding times normalized rapidly following bypass (8.5 +/- 1.4 min at 1 hr). The infusion of prostacyclin (PGI2) into the bubble oxygenator during bypass (40--80 ng/kg/min) prevented the prolongation in bleeding time (p less than 0.01 compared with untreated control values) but did not block the release of alpha-granule proteins. Dosages outside this range were associated with prolonged bleeding times. These results show that transient platelet dysfunction occurring during cardiopulmonary bypass represents activation of platelets independent of alpha or dense granule release and is blocked by potent short-acting inhibition of platelet function using PGI2 infused into the oxygenator apparatus at optimal therapeutic doses.

[1]  R. Bick Alterations of Hemostasis Associated With Cardiopulmonary Bypass: Pathophysiology, Prevention, Diagnosis, and Management , 1976, Seminars in thrombosis and hemostasis.

[2]  E. Hessel,et al.  Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. , 1980, Blood.

[3]  D. Longmore,et al.  PROSTACYCLIN: A SOLUTION TO SOME PROBLEMS OF EXTRACORPOREAL CIRCULATION Experiments in Greyhounds , 1979, The Lancet.

[4]  D. Pepper,et al.  The release, distribution, and clearance of human beta-thromboglobulin and platelet factor 4. , 1978, Thrombosis research.

[5]  M. Drillings,et al.  Radioimmunoassay of Platelet Factor 4 and β‐Thromboglobulin: Development and Application to Studies of Platelet Release in Relation to Fibrinopeptide A Generation , 1978, British journal of haematology.

[6]  R. Sautter,et al.  Platelet dysfunction associated with cardiopulmonary bypass. , 1978, The Annals of thoracic surgery.

[7]  H. Glueck,et al.  Measurement of Nucleotide Pools in Platelets Using High Pressure Liquid Chromatography , 1977, Thrombosis and Haemostasis.

[8]  R. Colman,et al.  Function of human platelets during extracorporeal circulation. , 1977, The American journal of physiology.

[9]  F. Bachmann,et al.  The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. , 1975, The Journal of thoracic and cardiovascular surgery.

[10]  C. Mielke,et al.  The standardized normal Ivy bleeding time and its prolongation by aspirin. , 1969, Blood.

[11]  L. Harker,et al.  Thrombokinetics in man. , 1969, The Journal of clinical investigation.

[12]  G. Born,et al.  The aggregation of blood platelets , 1963, The Journal of physiology.

[13]  E. Salzman Blood Platelets and Extracorporeal Circulation * , 1963, Kyobu geka. The Japanese journal of thoracic surgery.

[14]  R. Heyssel Determination of human platelet survival utilizing C-14-labeled serotonin. , 1961, The Journal of clinical investigation.

[15]  R. Ponlot,et al.  Haemostasis Disorders in Open Heart Surgery with Extracorporeal Circulation , 1977 .

[16]  S. Hanson,et al.  Simultaneous 51CR AND 14C-Serotonin Platelet Survival Measurements , 1977, Thrombosis and Haemostasis.

[17]  E. Murphy,et al.  The Estimation of Blood Platelet Survival II. The Multiple Hit Model , 1971, Thrombosis and Haemostasis.